Related Experiment Video
Updated: Jan 19, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
Immune checkpoint blockade in small cell lung cancer
Rebecca Y Tay1, David Heigener2, Martin Reck3
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Abstract:
Despite the highly immunogenic potential of small cell lung cancer (SCLC), progress in evaluating the therapeutic value of immune checkpoint agents has lagged behind that of non-small cell lung cancer. Results from a number of phase I-III clinical trials that specifically address the use of anti-PD-1, anti-PD-L1 and anti-CTLA-4 agents in SCLC have now been reported. This review will focus on the available evidence for immune checkpoint blockade in SCLC and review current biomarker strategies with the aim of providing perspective and interpretation of this data for clinical practice.
Related Concept Videos
09:45Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
09:57Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung
04:36Adenocarcinoma Engraftment: A Method to Implant Cancer Cells into the Murine Lungs
05:54An In Vitro Method to Identify Innate and Adaptive Immune Cells Residing in Murine Lungs
Neuromuscular Junction And Blockade

